The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
Open accessAbstract
Purpose: The current classification systems of myelodysplastic syndromes (MDS), including the International Prognostic Scoring System (IPSS), do not fully reflect the molecular heterogeneity of the disease. Molecular characterization may predict clinical outcome and help stratify patients for targeted therapies. Epigenetic therapy using decitabine, a DNA hypomethylating agent, is clinically effective for the treatment of MDS. Therefore, we investigated the association between DNA methylation and clinical outcome in MDS. Patients and Methods: We screened 24 patients with MDS for promoter CpG island methylation of 24 genes and identified aberrant hypermethylation at 10 genes. We then performed quantitative methylation analyses by bisulfite pyrosequencing of the identified genes in 317 patient samples from three independent studies and assessed relations between methylation and clinical outcome. Results: In an initial training cohort of 89 patients with MDS, methylation frequencies of individual genes ranged from 7% to 70% and were highly concordant. Therefore, we defined a methylation z score based on all genes for each patient. We found that patients with higher levels of methylation, compared with patients with lower levels, had a shorter median overall survival (12.3 v 17.5 months, respectively; P = .04) and shorter median progression-free survival (6.4 v 14.9 months, respectively; P = .009). This methylation prognostic model was independent of age, sex, and IPSS group. Applied to two validation cohorts (228 patients), this model was confirmed as an independent prognostic predictor for survival. Although methylation at baseline did not correlate with clinical response to decitabine, we observed a significant correlation between reduced methylation over time and clinical responses. Conclusion: DNA methylation predicts overall and progression-free survival in MDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
CpG island methylator phenotype in colorectal cancer
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J.-P. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8681 · Cited by 2,523
Self-citationKantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Self-citationAnalysis of Microarray Data Using Z Score Transformation
Cheadle, C., Vawter, M. P., Freed, W. J., & Becker, K. G. (2003) · The Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60455-2 · Cited by 1,146
Jones, R. (2002) · Nature Reviews Genetics · doi:10.1038/nrg962 · Cited by 828
Haase, D., Germing, U., Schanz, J., Pfeilstöcker, M., Nösslinger, T., Hildebrandt, B., Kundgen, A., Lübbert, M., Kunzmann, R., Giagounidis, A. A. N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-082404 · Cited by 794
Kantarjian, H., Oki, Y., Garcia-Manero, G., Huang, X., O'Brien, S., Cortes, J., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021162 · Cited by 685
Self-citationAberrant methylation in gastric cancer associated with the CpG island methylator phenotype.
Toyota, M., Ahuja, N., Suzuki, H., Itoh, F., Ohe-Toyota, M., Imai, K., Baylin, S. B., & Issa, J. J. (1999) · PubMed · Cited by 530
Self-citationSensitive and quantitative universal Pyrosequencing™ methylation analysis of CpG sites
Colella, S., Shen, L., Baggerly, K. A., Issa, J.-P. J., & Krahe, R. (2003) · BioTechniques · doi:10.2144/03351md01 · Cited by 514
Self-citationValent, P., Horny, H.-P., Bennett, J. M., Fonatsch, C., Germing, U., Greenberg, P., Haferlach, T., Haase, D., Kolb, H.-J., Krieger, O., et al. (2007) · Leukemia Research · doi:10.1016/j.leukres.2006.11.009 · Cited by 513
Boyes, J., & Bird, A. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05055.x · Cited by 471
Methylation profiling of CpG islands in human breast cancer cells
Huang, T. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.3.459 · Cited by 427
Hypermethylation of multiple genes in pancreatic adenocarcinoma.
Ueki, T., Toyota, M., Sohn, T. A., Yeo, C. J., Issa, J. J., Hruban, R. H., & Goggins, M. (2000) · PubMed · Cited by 407
Self-citationQuesnel, B., Guillerm, G., Vereecque, R., Wattel, E., Preudhomme, C., Bauters, F., Vanrumbeke, M., & Fenaux, P. (1998) · Blood · doi:10.1182/blood.v91.8.2985.2985_2985_2990 · Cited by 342
Methylation profiling in acute myeloid leukemia
Toyota, M., Kopecky, K. J., Toyota, M.-O., Jair, K.-W., Willman, C. L., & Issa, J.-P. J. (2001) · Blood · doi:10.1182/blood.v97.9.2823 · Cited by 324
Self-citationDNA Methylation as a Therapeutic Target in Cancer
Issa, J.-P. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2076 · Cited by 301
Self-citationDNA Methylation and Environmental Exposures in Human Hepatocellular Carcinoma
Shen, L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.10.755 · Cited by 249
Self-citationIssa, J. J., Baylin, S. B., & Belinsky, S. A. (1996) · PubMed · Cited by 178
Self-citationAggerholm, A., Holm, M. S., Guldberg, P., Olesen, L. H., & Hokland, P. (2006) · European Journal of Haematology · doi:10.1111/j.1600-0609.2005.00559.x · Cited by 176
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2003) · Leukemia · doi:10.1038/sj.leu.2403054 · Cited by 176
Gilliland, D. G. (2001) · Current Opinion in Hematology · doi:10.1097/00062752-200107000-00001 · Cited by 161
Tien, H., Tang, J., Tsay, W., Liu, M., Lee, F., Wang, C., Chen, Y., & Shen, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02496.x · Cited by 160
Shen, L., Toyota, M., Kondo, Y., Obata, T., Daniel, S., Pierce, S. A., Imai, K., Kantarjian, H. M., Issa, J. J., & Garcia‐Manero, G. (2003) · Blood · doi:10.1182/blood-2002-08-2466 · Cited by 128
Self-citationDNA Methylation Differences Associated with Tumor Tissues Identified by Genome Scanning Analysis
Liang, G., Salem, C. E., Yu, M. C., Nguyen, H. D., Gonzales, F. A., Nguyen, T. T., Nichols, P. W., & Jones, P. A. (1998) · Genomics · doi:10.1006/geno.1998.5502 · Cited by 114
The establishment and maintenance of DNA methylation patterns in mouse somatic cells
Turker, M. S. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1999.0133 · Cited by 79
Boumber, Y., Kondo, Y., Chen, X., Shen, L., Gharibyan, V., Konishi, K., Estey, E. H., Kantarjian, H. M., Garcia‐Manero, G., & Issa, J. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3093 · Cited by 74
Self-citationDNA Methylation as a Therapeutic Target in Cancer
Issa, J. J. (2008) · AACR Education book · doi:10.1158/aacr.edb-ccr-06-2076 · Cited by 54
Self-citationGrövdal, M., Khan, R., Aggerholm, A., Antunović, P., Astermark, J., Bernell, P., Engström, L.-M., Kjeldsen, L., Linder, O., Nilsson, L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1193 · Cited by 52
Clinical implications ofSOCS1methylation in myelodysplastic syndrome
Wu, S., Yao, M., Chou, W., Tang, J., Chen, C., Ko, B.-S., Huang, S.-Y., Tsay, W., Chen, Y., Shen, M., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06293.x · Cited by 33
Toyota, M., & Issa, J. J. (2003) · Humana Press eBooks · doi:10.1385/1-59259-182-5:101 · Cited by 9
Self-citationIdentification of 41 Novel Promoter-Associated CpG Islands Methylated in Leukemias.
Jelı́nek, J., Mannari, R. K., & Issa, J. J. (2004) · Blood · doi:10.1182/blood.v104.11.1126.1126 · Cited by 5
Self-citation
Cited by
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J.-P. J., & Baylin, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,128
Self-citationTP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605949 · Cited by 796
Morschhauser, F., Tilly, H., Chaidos, A., McKay, P., Phillips, T., Assouline, S., Batlevi, C. L., Campbell, P., Ribrag, V., Damaj, G. L., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30441-1 · Cited by 604
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Bejar, R., Lord, A., Stevenson, K., Bar-Natan, M., Pérez-Ladaga, A., Zaneveld, J., Wang, H., Caughey, B., Stojanov, P., Getz, G., et al. (2014) · Blood · doi:10.1182/blood-2014-06-582809 · Cited by 562
Self-citation
Metadata
- Authors
- Shen, L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S., Zhu, W., Pierce, S., Kondo, Y., Oki, Y., Jelinek, J., Saba, H., Estey, E., & Issa, J.-P. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-02-01
- Volume
- 28
- Issue
- 4
- Pages
- 605-613
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166506757
- Cited by
- 355
- References
- 31
- FWCI
- 19.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.